Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ERBB2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03734029
What this trial is testing

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Who this might be right for
Breast Cancer
Daiichi Sankyo 557
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439136
What this trial is testing

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Study completedNCT02073487
What this trial is testing

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Who this might be right for
Breast Cancer
The Methodist Hospital Research Institute 32
Testing effectiveness (Phase 2)Looking for participantsNCT05575804
What this trial is testing

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Who this might be right for
Advanced/ Metastatic Her-2 Positive Breast Cancer
Fudan University 32
Early research (Phase 1)Ended earlyNCT00251433
What this trial is testing

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 53
Not applicableLooking for participantsNCT05573893
What this trial is testing

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Who this might be right for
Breast NeoplasmsBreast CancerNeoplasm Metastasis
AstraZeneca 800
Testing effectiveness (Phase 2)Study completedNCT02018458
What this trial is testing

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

Who this might be right for
Breast Cancer
Baylor Research Institute 10
Large-scale testing (Phase 3)Looking for participantsNCT06899126
What this trial is testing

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Daiichi Sankyo 686
Early research (Phase 1)Active Not RecruitingNCT03807778
What this trial is testing

Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Takeda 53
Testing effectiveness (Phase 2)Study completedNCT00811135
What this trial is testing

Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 88
Not applicableLooking for participantsNCT04517838
What this trial is testing

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Who this might be right for
Breast AdenocarcinomaHER2-Positive Breast CarcinomaAnatomic Stage I Breast Cancer AJCC v8+3 more
Mayo Clinic 230
Very early researchLooking for participantsNCT05245058
What this trial is testing

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd 150
Testing effectiveness (Phase 2)UnknownNCT06574763
What this trial is testing

Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sun Yat-sen University 47
Large-scale testing (Phase 3)Looking for participantsNCT06977893
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 194
Testing effectiveness (Phase 2)Active Not RecruitingNCT04482309
What this trial is testing

T-DXd in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca 477
Testing effectiveness (Phase 2)UnknownNCT03147963
What this trial is testing

Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07691333
What this trial is testing

Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Breast CancerBreast Neoplasms
Fujian Cancer Hospital 35
Testing effectiveness (Phase 2)Study completedNCT00096993
What this trial is testing

Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Genentech, Inc. 131
Testing effectiveness (Phase 2)Active Not RecruitingNCT05826964
What this trial is testing

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Who this might be right for
Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+1 more
University of Miami 24
Testing effectiveness (Phase 2)Looking for participantsNCT05900206
What this trial is testing

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Karolinska University Hospital 370
Next Page